Riboflavin and UV-A light treatment of both eyes together for keratoconus
Tests same-day treatment of both eyes in people with keratoconus.
Key facts
- Who runs it
- Glaukos Corporation
- Where
- Westerville, United StatesSee the site
- Trial code
- Registry title
- Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 15 people, planned
- Started
- 11 May 2026
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- Riboflavin Ophthalmic Solutions
- UV-A Irradiation System
- Record updated
- 5 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with keratoconus in both eyes. It tests corneal cross-linking done in both eyes on the same day.
- Age
- 13 Years and older
- Sex
- All
- Disease stage
- Keratoconus diagnosed in each eye.
- Earlier treatment
- No prior corneal cross-linking in either eye.
Main reasons for not taking part
- Known allergy or sensitivity to the study medicines
- History of corneal disease
- Prior corneal cross-linking in either eye
- Pregnant, nursing, or planning pregnancy during the study
- Took part in another trial of an experimental drug or device within 30 days
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Provide written informed consent
- Willing and able to comply with study instructions and follow-up visits
- Diagnosis of keratoconus in each eye
Who cannot take part
- Prior corneal cross-linking in either eye
- Participated in other investigational drug or device trial within 30 days of the study
- Known allergy or sensitivity to study medications
- History of corneal disease
- Pregnant, nursing, or planning pregnancy during the study period
Where in United States
- Westerville, OhioHospital not named in the registryContact: Study Director, MDTaking people
About the trial
What the trial wants to find out
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
The group in the trial
- Epioxa™ HD/Epioxa™ and UV-A IrradiationTreatment being tested
Epioxa™ HD/Epioxa™ and UV-A Irradiation using the O2n™ System and Supplemental Oxygen using the Boost Goggles®
Treatment: Riboflavin Ophthalmic Solutions and UV-A Irradiation System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD/Epioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus
- Plain-language title
- Riboflavin and UV-A light treatment of both eyes together for keratoconusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 5 June 2026